Brain metastasis breast cancer trial with hormone therapy plus SPH4336
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can and will sign the study consent form and join voluntarily
- Your performance status is 0 or 1 (you’re up and about most of the time)
- You’re expected to live at least 3 months
- Your breast cancer has spread and you can’t have curative surgery or other local treatments
- You have at least one measurable spot doctors can track on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
This study tests whether adding SPH4336 to letrozole works better than letrozole plus a placebo for treating hormone-receptor–positive, HER2-negative breast cancer in people starting first-line treatment. It may help slow cancer growth more effectively if the added drug is beneficial.
This trial tests a combination of radiation to the brain, a hormone therapy, and a targeted drug called dalpiciclib for people with advanced breast cancer that has spread to the brain. The goal is to see if this combination can help control the cancer in the brain and elsewhere.
This trial tests two new drugs, SHR-A1811 and THPy, for women with HER2-positive advanced breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and improve outcomes for patients who have not yet had systemic treatment for advanced disease.
Hear when a new Breast Cancer Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.